SomaGenics specializes in advanced RNA analysis and RNA-based therapeutics, leveraging innovative technologies to enhance the detection and quantification of small RNAs, particularly microRNAs (miRNAs). Their proprietary miR-ID® technology employs a circularization-based reverse transcription quantitative PCR (RT-qPCR) method, which allows for highly sensitive and specific detection of miRNAs, including the ability to discriminate single nucleotide polymorphisms (SNPs) within these molecules. This technology is versatile, functioning effectively with various sample types, including total RNA, cell lysates, and biofluids. Complementing this, the miR-Direct® method enables direct quantification of miRNAs from serum and plasma, addressing common challenges such as inconsistent RNA recovery and PCR inhibition, thereby facilitating accurate biomarker discovery.

In addition to their RNA analysis capabilities, SomaGenics has developed a unique class of RNA-based therapeutics known as short interfering RNAs (sshRNAs). These sshRNAs exhibit remarkable potency and favorable pharmacokinetic properties while minimizing immune stimulation, distinguishing them from traditional RNA interference (RNAi) approaches. Currently, SomaGenics is advancing two therapeutic programs utilizing sshRNA technology, focusing on applications in wound healing and hepatitis delta virus (HDV) treatment. Through these innovative technologies, SomaGenics aims to contribute significantly to the fields of molecular diagnostics and therapeutic development.

United States

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection (NGS, quantitative PCR) of small or fragmented RNA, including microRNA.

Somagenics

Company Details